2-Aethyl-5-isopropyl-thiazol | 66577-44-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-Aethyl-5-isopropyl-thiazol
• 英文别名: 2-Ethyl-5-propan-2-yl-1,3-thiazole
• CAS: 66577-44-4
• 化学式: C₈H₁₃NS
• 分子量: 155.264
• InChiKey: UODQRFWUSZRUDN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-溴-3-甲基丁醛 、 丙酰胺 生成 2-Aethyl-5-isopropyl-thiazol
  参考文献：
  名称：

  Poite,M.; Metzger,J., Bulletin de la Societe Chimique de France, 1962, p. 2078 - 2085

  摘要：

  DOI：

文献信息

• [EN] LINKED DIBENZIMIDAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS DU DIBENZIMIDAZOLE LIÉS
  申请人：ENANTA PHARM INC

  公开号：WO2010091413A1

  公开（公告）日：2010-08-12

  The present invention discloses linked dibenzimidazole derivatives, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了联苯二咪唑衍生物，或其药学上可接受的盐、酯或前药，其抑制含RNA的病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
• Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same
  申请人：Lee Jin Soo

  公开号：US20100240890A1

  公开（公告）日：2010-09-23

  The present invention relates to novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same. The novel benzamidine derivatives of the present invention are useful for the prevention and treatment of osteoporosis, bone fractures and allergic inflammatory diseases.

  本发明涉及新型苯甲酰胺衍生物、其制备方法以及包含其的药物组合物。本发明的新型苯甲酰胺衍生物对于预防和治疗骨质疏松、骨折和过敏性炎症疾病有用。
• Inhibitors of cyclin-dependent kinase 7 (CDK7)
  申请人：SYROS PHARMACEUTICALS, INC.

  公开号：US10336760B2

  公开（公告）日：2019-07-02

  The present invention provides novel compounds described herein, such as of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

  本发明提供了本文所述的新型化合物，如式（I）化合物，及其药学上可接受的盐、溶液剂、水合物、同系物、立体异构体、同位素标记的衍生物和组合物。还提供了涉及这些化合物或组合物的方法和试剂盒，用于治疗或预防受试者的增殖性疾病（如癌症（如白血病、黑色素瘤、多发性骨髓瘤）、良性肿瘤、血管生成、炎症性疾病、自身炎症性疾病和自身免疫性疾病）。使用本发明的化合物或组合物治疗患有增殖性疾病的受试者，可抑制细胞周期蛋白依赖性激酶7（CDK7）的异常活性，从而诱导细胞凋亡和/或抑制受试者体内的转录。
• Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
  申请人：Cymabay Therapeutics, Inc.

  公开号：US10292983B2

  公开（公告）日：2019-05-21

  Use of oxymethylene aryl GPR119 agonists, and optionally DPP IV inhibitors and optionally metformin, for the treatment of inflammatory gastrointestinal diseases or gastrointestinal conditions involving malabsorption of nutrients and/or fluids are provided.

  提供了氧亚甲基芳基 GPR119 激动剂、可选的 DPP IV 抑制剂和可选的二甲双胍用于治疗炎症性胃肠道疾病或涉及营养和/或液体吸收不良的胃肠道疾病。
• Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
  申请人：Incyte Corporation

  公开号：US10398699B2

  公开（公告）日：2019-09-03

  The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

  本发明提供了杂芳基取代的吡咯并[2,3-b]吡啶和杂芳基取代的吡咯并[2,3-b]嘧啶，它们可以调节 Janus 激酶的活性，并可用于治疗与 Janus 激酶活性有关的疾病，例如包括免疫相关疾病、皮肤疾病、骨髓增生性疾病、癌症和其他疾病。